Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 1/2014

01-01-2014 | Educational Review

Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013

Authors: Caitlin E. Carter, Nadine M. Benador

Published in: Pediatric Nephrology | Issue 1/2014

Login to get access

Abstract

Therapeutic plasma exchange is an extracorporeal treatment modality that removes systemic circulating pathologic factors or replaces absent plasma components and plays a role in many nephrologic conditions. It presents a number of technical challenges in the pediatric population but has become an increasingly common practice in pediatric nephrology over the past several decades. While prospective evidence is often lacking, our increased understanding of the molecular pathogenesis underlying many pediatric renal diseases provides sound reasoning for the use of plasma exchange in treating these conditions. This review will present the currently accepted indications for plasma exchange in children, the technical aspects of the procedure and its potential complications.
Literature
1.
Abel JJ, Rowntree LG, Turner BB (1914) Plasma removal with return of corpuscles. J Pharmacol Exp Ther 5:625–641
2.
Schwab PJ, Fahey JL (1960) Treatment of Waldenstrom’s macroglobulinemia by plasmapheresis. N Engl J Med 263:574–579PubMed
3.
Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH (2010) Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 25:83–177PubMed
4.
Balogun RA, Kaplan A, Ward DM, Okafor C, Burns TM, Torloni AS, Macik BG, Abdel-Rahman EM (2010) Clinical applications of therapeutic apheresis. J Clin Apher 25:250–264PubMed
5.
Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS (2011) Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 11:719–724PubMed
6.
Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S (2006) A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor-specific alloantibody. Am J Transplant 6:346–351PubMed
7.
Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS (2008) Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 3:1160–1167PubMed
8.
Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J (2009) Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 87:268–273PubMed
9.
Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL (2011) Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365:318–326PubMed
10.
Pradhan M, Raffaelli RM, Lind C, Meyers KE, Kaplan BS, Baluarte HJ, Monos D (2008) Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis. Pediatr Transplant 12:711–716PubMed
11.
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359:242–251PubMed
12.
Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC (2010) Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89:1095–1102PubMed
13.
Jordan SC, Vo AA (2012) Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. Am J Kidney Dis 59:758–760PubMed
14.
Wu A, Buhler LH, Cooper DK (2003) ABO-incompatible organ and bone marrow transplantation: current status. Transpl Int 16:291–299PubMed
15.
Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB (2004) Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apher 19:79–85PubMed
16.
Ishida H, Koyama I, Sawada T, Utsumi K, Murakami T, Sannomiya A, Tsuji K, Yoshimura N, Tojimbara T, Nakajima I, Tanabe K, Yamaguchi Y, Fuchinoue S, Takahashi K, Teraoka S, Ito K, Toma H, Agishi T (2000) Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 70:681–685PubMed
17.
Tobian AA, Shirey RS, Montgomery RA, Cai W, Haas M, Ness PM, King KE (2010) ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 10:1247–1253PubMed
18.
Tobian AA, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE (2009) Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 49:1248–1254PubMed
19.
Sivakumaran P, Vo AA, Villicana R, Peng A, Jordan SC, Pepkowitz SH, Klapper EB (2009) Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. J Clin Apher 24:155–160PubMed
20.
Shishido S, Hyodo YY, Aoki Y, Takasu J, Kawamura T, Sakai KK, Aikawa AA, Satou H, Muramatsu MM, Matsui Z (2012) Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls. Transplant Proc 44:214–216PubMed
21.
Shishido S, Asanuma H, Tajima E, Hoshinaga K, Ogawa O, Hasegawa A, Honda M, Nakai H (2001) ABO-incompatible living-donor kidney transplantation in children. Transplantation 72:1037–1042PubMed
22.
Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y (2004) Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089–1096PubMed
23.
Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G (2008) ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 85:1745–1754PubMed
24.
Tyden G, Kumlien G, Berg UB (2011) ABO-incompatible kidney transplantation in children. Pediatr Transplant 15:502–504PubMed
25.
Puttarajappa C, Shapiro R, Tan HP (2012) Antibody-mediated rejection in kidney transplantation: a review. J Transplant 2012:193724PubMed
26.
Dragun D (2007) Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant 22:1819–1822PubMed
27.
Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Kahwaji J, Vo AA, Jordan SC, Dragun D (2010) Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in donor HLA antibody negative patients. Transplantation 90:1473–1477PubMed
28.
Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M (2008) Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753–760PubMed
29.
Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao K, Villicana R, Toyoda M, Kahwaji J, Vo AA (2010) Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 25:2035–2045, quiz 2045–2038PubMed
30.
Ahmed T, Senzel L (2012) The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection. J Clin Apher 27:173–177PubMed
31.
Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR (2003) Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75:1490–1495PubMed
32.
Brown CM, Abraham KA, O’Kelly P, Conlon PJ, Walshe JJ (2009) Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 41:3690–3692PubMed
33.
Gomes AM, Pedroso S, Martins LS, Malheiro J, Viscayno JR, Santos J, Dias L, Henriques AC, Sarmento AM, Cabrita A (2009) Diagnosis and treatment of acute humoral kidney allograft rejection. Transplant Proc 41:855–858PubMed
34.
Kranz B, Kelsch R, Kuwertz-Broking E, Brocker V, Wolters HH, Konrad M (2011) Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 26:1149–1156PubMed
35.
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C (2009) Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9:1099–1107PubMed
36.
Bohmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, Soliman T, Bauer P, Mullner M, Druml W (2007) Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 7:117–121PubMed
37.
Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883PubMed
38.
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23:2051–2059PubMed
39.
Fine RN (2007) Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 22:496–502PubMed
40.
Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD (2009) Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87:1232–1239PubMed
41.
Senggutuvan P, Cameron JS, Hartley RB, Rigden S, Chantler C, Haycock G, Williams DG, Ogg C, Koffman G (1990) Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 4:21–28PubMed
42.
Hubsch H, Montane B, Abitbol C, Chandar J, Shariatmadar S, Ciancio G, Burke G, Miller J, Strauss J, Zilleruelo G (2005) Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol 20:210–216PubMed
43.
Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F (1992) Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 92:375–383PubMed
44.
Fuentes GM, Meseguer CG, Carrion AP, Hijosa MM, Garcia-Pose A, Melgar AA, Torres MN (2010) Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 25:529–534PubMed
45.
Andresdottir MB, Ajubi N, Croockewit S, Assmann KJ, Hibrands LB, Wetzels JF (1999) Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange. Nephrol Dial Transplant 14:2650–2656PubMed
46.
Deegens JK, Andresdottir MB, Croockewit S, Wetzels JF (2004) Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 17:151–157PubMed
47.
Greenstein SM, Delrio M, Ong E, Feuerstein D, Schechner R, Kim D, Corey H, Kaskel R, Tellis VA, Moritz ML (2000) Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. Pediatr Nephrol 14:1061–1065PubMed
48.
Fencl F, Simkova E, Vondrak K, Janda J, Chadimova M, Stejskal J, Seeman T (2007) Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports. Transplant Proc 39:3488–3490PubMed
49.
Cochat P, Kassir A, Colon S, Glastre C, Tourniaire B, Parchoux B, Martin X, David L (1993) Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide. Pediatr Nephrol 7:50–54PubMed
50.
Schachter AD, Harmon WE (2001) Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant 5:406–409PubMed
51.
Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K (2001) Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in child, 52en. Transplantation 71:628–633PubMed
52.
Couloures K, Pepkowitz SH, Goldfinger D, Kamil ES, Puliyanda DP (2006) Preventing recurrence of focal segmental glomerulosclerosis following renal transplantation: a case report. Pediatr Transplant 10:962–965PubMed
53.
Jungraithmayr TC, Hofer K, Cochat P, Chernin G, Cortina G, Fargue S, Grimm P, Knueppel T, Kowarsch A, Neuhaus T, Pagel P, Pfeiffer KP, Schafer F, Schonermarck U, Seeman T, Toenshoff B, Weber S, Winn MP, Zschocke J, Zimmerhackl LB (2011) Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 22:579–585PubMed
54.
Dall’Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, Zennaro C, Basile G, Montini G, Rivabella L, Cardillo M, Scalamogna M, Ginevri F (1999) Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 34:1048–1055PubMed
55.
Baum MA (2004) Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 8:329–333PubMed
56.
Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M (2011) Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 15:495–501PubMed
57.
Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M, McCarthy ET, Savin VJ (2005) Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5:2907–2912PubMed
58.
de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noel LH, Ferrario F, Waldherr R, Bruijn JA, Bajema IM, Hagen EC, Pusey CD (2007) Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 18:2189–2197PubMed
59.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188PubMed
60.
Zauner I, Bach D, Braun N, Kramer BK, Funfstuck R, Helmchen U, Schollmeyer P, Bohler J (2002) Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 39:28–35PubMed
61.
Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K (1992) A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 20:261–269PubMed
62.
Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED (2007) Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum 57:837–844PubMed
63.
Nash MC, Jones CL, Walker RG, Powell HR (1993) Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in children. Pediatr Nephrol 7:11–14PubMed
64.
Stegmayr BG, Gothefors L, Malmer B, Muller Wiefel DE, Nilsson K, Sundelin B (2000) Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol 14:208–213PubMed
65.
Levy JB, Turner AN, Rees AJ, Pusey CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042PubMed
66.
Martini A, Binda S, Mariani G, Scotta MS, Ruberto G (1981) Goodpasture’s syndrome in a child: natural history and effect of treatment. Acta Paediatr Scand 70:435–439PubMed
67.
Shah MK, Hugghins SY (2002) Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J 95:1411–1418PubMed
68.
Johnson JP, Moore J Jr, Austin HA 3rd, Balow JE, Antonovych TT, Wilson CB (1985) Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 64:219–227
69.
Pusey CD (2003) Anti-glomerular basement membrane disease. Kidney Int 64:1535–1550PubMed
70.
Williamson SR, Phillips CL, Andreoli SP, Nailescu C (2011) A 25-year experience with pediatric anti-glomerular basement membrane disease. Pediatr Nephrol 26:85–91PubMed
71.
Dewan D, Gulati S, Sharma RK, Prasad N, Jain M, Gupta A, Kumar A (2008) Clinical spectrum and outcome of crescentic glomerulonephritis in children in developing countries. Pediatr Nephrol 23:389–394PubMed
72.
Jardim HM, Leake J, Risdon RA, Barratt TM, Dillon MJ (1992) Crescentic glomerulonephritis in children. Pediatr Nephrol 6:231–235PubMed
73.
Gilvarry J, Doyle GF, Gill DG (1992) Good outcome in anti-glomerular basement membrane nephritis. Pediatr Nephrol 6:244–246PubMed
74.
Bakkaloglu SA, Kasapkara CS, Soylemezoglu O, Peru H, Fidan K, Hasanoglu E, Buyan N (2006) Successful management of anti-GBM disease in a 5 1/2-year-old girl. Nephrol Dial Transplant 21:2979–2981PubMed
75.
Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326:1373–1379PubMed
76.
Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH (1998) Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 13:163–166PubMed
77.
Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M (1999) Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schonlein purpura nephritis in children. Am J Kidney Dis 33:427–433PubMed
78.
Shenoy M, Ognjanovic MV, Coulthard MG (2007) Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol 22:1167–1171PubMed
79.
Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, Suzuki S, Suzuki H (2004) Plasmapheresis therapy for rapidly progressive Henoch-Schonlein nephritis. Pediatr Nephrol 19:920–923PubMed
80.
Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70:423–431PubMed
81.
Loirat C, Noris M, Fremeaux-Bacchi V (2008) Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 23:1957–1972PubMed
82.
Noris M, Remuzzi G (2005) Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Nat Clin Pract Nephrol 1:2–3PubMed
83.
Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Komhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283–1291PubMed
84.
Noris M, Remuzzi G (2010) Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 30:395–408PubMed
85.
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187PubMed
86.
Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687–696PubMed
87.
Bukowski RM, King JW, Hewlett JS (1977) Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 50:413–417PubMed
88.
Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 1:88–99PubMed
89.
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–397PubMed
90.
Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400PubMed
91.
Kim JJ, Goodship TH, Tizard J, Inward C (2011) Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 26:2073–2076PubMed
92.
Nathanson S, Fremeaux-Bacchi V, Deschenes G (2001) Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 16:554–556PubMed
93.
Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L (2001) Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138:412–417PubMed
94.
Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279PubMed
95.
Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707–710PubMed
96.
Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 26:2085–2088PubMed
97.
Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360:544–546PubMed
98.
Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P (2011) Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 26:621–624PubMed
99.
Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P (2011) Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488–1494PubMed
100.
Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W (2010) Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 362:1746–1748PubMed
101.
Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S (2011) Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 26:1325–1329PubMed
102.
Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ (1999) Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 27:2096–2104PubMed
103.
Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D (2005) Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23:494–500PubMed
104.
Busund R, Koukline V, Utrobin U, Nedashkovsky E (2002) Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 28:1434–1439PubMed
105.
Sinha A, Tiwari AN, Chanchlani R, Seetharamanjaneyulu V, Hari P, Bagga A (2012) Therapeutic plasmapheresis using membrane plasma separation. Indian J Pediatr 79:1084–1086PubMed
106.
Ciechanska E, Segal L, Wong H, Chretien C, Feber J, Filler G (2005) Plasma exchange using a continuous venovenous hemofiltration machine in children. Blood Purif 23:440–445PubMed
107.
Yorgin PD, Eklund DK, al-Uzri A, Whitesell L, Theodorou AA (2000) Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration. Pediatr Nephrol 14:18–21PubMed
108.
Jhang J, Middlesworth W, Shaw R, Charette K, Papa J, Jefferson R, Torloni AS, Schwartz J (2007) Therapeutic plasma exchange performed in parallel with extra corporeal membrane oxygenation for antibody-mediated rejection after heart transplantation. J Clin Apher 22:333–338PubMed
109.
Bunchman TE, Brophy PD, Goldstein SL (2008) Technical considerations for renal replacement therapy in children. Semin Nephrol 28:488–492PubMed
110.
Michon B, Moghrabi A, Winikoff R, Barrette S, Bernstein ML, Champagne J, David M, Duval M, Hume HA, Robitaille N, Belisle A, Champagne MA (2007) Complications of apheresis in children. Transfusion 47:1837–1842PubMed
111.
Zaritsky JJ, Salusky IB, Gales B, Ramos G, Atkinson J, Allsteadt A, Brandt ML, Goldstein SL (2008) Vascular access complications in long-term pediatric hemodialysis patients. Pediatr Nephrol 23:2061–2065PubMed
112.
Maki DG, Ringer M, Alvarado CJ (1991) Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338:339–343PubMed
113.
Goldstein SL, Klaus G, Friedman DF, Kim HC (2012) Pediatric therapeutic apheresis. In: Warady (ed) Pediatric dialysis. Springer, New York, pp 775–796
114.
Russell SJ (1949) Blood volume studies in healthy children. Arch Dis Child 24:88–98PubMed
115.
JR Geigy AG, Diem K, Lentner C (1970) Geigy Scientific Tables, 7th Edition, Basel, Switzerland
116.
Nadler SB, Hidalgo JH, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224–232PubMed
117.
Pinkard SL, O’Leary MF, Carey PM (2012) Blood priming for apheresis on the COBE spectra: should red cell units be diluted or not? Abstracts from the American Society for Apheresis 33rd Annual Meeting, April 11–14, 2012, Atlanta, Georgia. J Clin Apher 27:30
118.
Jung S, Kang ES, Ki CS, Kim DW, Paik KH, Chang YS (2011) Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome. J Clin Apher 26:162–165PubMed
119.
Delaney MSS, Capocelli KE, Schneiderman J, Wong EC, Eder A, Kim HC (2012) A survey of pediatric apheresis practice. Abstracts from the American Society for Apheresis 33rd Annual Meeting, April 11–14, 2012, Atlanta, Georgia. J Clin Apher 27:2
120.
Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A (2003) Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 31:2450–2455PubMed
121.
Lee G, Arepally GM (2012) Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher 27:117–125PubMed
122.
Antonic M, Gubensek J, Buturovic-Ponikvar J, Ponikvar R (2009) Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial 13:322–326PubMed
123.
Reverberi R, Reverberi L (2007) Removal kinetics of therapeutic apheresis. Blood Transfus 5:164–174PubMed
124.
Hattersley JG, Chappell MJ, Zehnder D, Higgins RM, Evans ND (2012) Describing the effectiveness of immunosuppression drugs and apheresis in the treatment of transplant patients. Comput Meth Programs Biomed 109:126–133
125.
McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, Smith JW (1999) Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 39:282–288PubMed
126.
Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ (2007) Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 27:1529–1549PubMed
127.
Slonim AD, Joseph JG, Turenne WM, Sharangpani A, Luban NL (2008) Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 48:73–80PubMed
128.
Pohl MA, Lan SP, Berl T (1991) Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 114:924–929PubMed
129.
Wood L, Jacobs P (1986) The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels. J Clin Apher 3:124–128PubMed
130.
Hanafusa N (2011) Theoretical basis of pathogenic substance removal during plasmapheresis. Ther Apher Dial 15:421–430PubMed
131.
Brecher ME, Owen HG, Collins ML (1993) Apheresis and ACE inhibitors. Transfusion 33:963–964PubMed
Metadata
Title
Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013
Authors
Caitlin E. Carter
Nadine M. Benador
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 1/2014
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2479-7

Other articles of this Issue 1/2014

Pediatric Nephrology 1/2014 Go to the issue

Original Article

Racial disparities in paediatric kidney transplantation

Clinical Quiz

A rare cause of systemic hypertension in an African child: Answers

Original Article

Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome

Original Article

Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses

Original Article

High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications

Review

Fluid management in the critically ill child